1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. NOXXON Pharma N.V.
  6. Summary
    ALNOX   NL0012044762

NOXXON PHARMA N.V.

(ALNOX)
  Report
Real-time Euronext Paris  -  05/19 11:35:19 am EDT
0.0811 EUR   -4.59%
05:06aNoxxon Obtains Additional $1 Million in Remaining Tranches of Equity-linked Facility
MT
05/17Noxxon announces results of the extraordinary general meeting of shareholders
AQ
05/11Noxxon Pharma N.V. Announces Scientific Advisory Board Appointments
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
05/13/2022 05/16/2022 05/17/2022 05/18/2022 05/19/2022 Date
0.0929(c) 0.0901(c) 0.09(c) 0.085(c) 0.0811(c) Last
226 073 43 701 186 511 290 312 413 672 Volume
+2.99% -3.01% -0.11% -5.56% -4.59% Change
More quotes
Estimated financial data (e)
Sales 2022 13,4 M 14,1 M 14,1 M
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Sales 2023 62,2 M 65,3 M 65,3 M
Net income 2023 - - -
Net Debt 2023 - - -
P/E ratio 2023 -
Yield 2023 -
Capitalization 7,16 M 7,51 M 7,51 M
Capi. / Sales 2022 0,53x
Capi. / Sales 2023 0,12x
Nbr of Employees 13
Free-Float 12,3%
More Financials
Company
NOXXON Pharma N.V. is a biopharmaceutical company specialized in the research and development of oncology products that act by neutralizing chemokines in the tumor microenvironment. NOXXON Pharma N.V.'s approach works in combination with other forms of treatment to enable greater therapeutic impact. The lead program, NOX-A12, has generated final clinical data from a combination trial with the immuno-oncology... 
More about the company
All news about NOXXON PHARMA N.V.
05:06aNoxxon Obtains Additional $1 Million in Remaining Tranches of Equity-linked Facility
MT
05/17Noxxon announces results of the extraordinary general meeting of shareholders
AQ
05/11Noxxon Pharma N.V. Announces Scientific Advisory Board Appointments
CI
04/22NOXXON Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
04/22Noxxon announces eur2.375 million financing under agreement with atlas
AQ
04/22NOXXON PHARMA N.V. : Annual Report
CO
04/22NOXXON Pharma N.V. Auditor Raises 'Going Concern' Doubt
CI
04/22NOXXON PHARMA N.V. : Annual results
CO
04/07Top-line results from noxxon's nox-a12 phase 1/2 gloria trial in brain cancer to be pre..
AQ
04/06NOXXON PHARMA N : Top-line results from NOXXONs NOX-A12 Phase 1/2 GLORIA trial in brain ca..
PU
04/06Top-Line Results from NOXXON’S NOX-A12 Phase 1/2 GLORIA Trial in Brain Cancer to B..
CI
03/24NOXXON Announces Top-Line Data of Phase 1/2 GLORIA Study With NOX-A12 in Partially Rese..
CI
01/31Noxxon announces eur2.375 million financing under agreement with atlas
AQ
01/30Cancer-Focused Biotech Noxxon Secures Additional $2.7 Million Financing
MT
01/27Noxxon - half-yearly report on the liquidity contract with invest securities
AQ
More news
News in other languages on NOXXON PHARMA N.V.
05:06aNoxxon obtient un million de dollars supplémentaires dans les tranches restantes de la ..
05/11Noxxon Pharma N.V. annonce des nominations au conseil consultatif scientifique
04/25NOXXON : augmentation de capital en vue, le titre recule
04/25Une bonne gueule de bois
04/22NOXXON Pharma N.V. annonce ses résultats pour l'exercice complet clos le 31 décembre 20..
More news
Chart NOXXON PHARMA N.V.
Duration : Period :
NOXXON Pharma N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOXXON PHARMA N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,09 €
Average target price 0,83 €
Spread / Average Target 876%
Managers and Directors
Aram Andrew Mangasarian Chief Executive Officer & Director
Bryan Jennings Chief Financial Officer & Statutory Director
Maurizio PetitBon Chairman-Supervisory Board
Bertram K÷hler Member-Supervisory Board
Cornelis Alexander Izeboud Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
NOXXON PHARMA N.V.-63.68%8
MODERNA, INC.-45.78%54 775
LONZA GROUP AG-29.81%40 137
IQVIA HOLDINGS INC.-30.08%37 337
SEAGEN INC.-7.50%26 323
ICON PUBLIC LIMITED COMPANY-34.37%16 524